Switching study gives Celltrion biosim more ammo in Remicade fight

Celltrion is working hard to snatch market share from Merck's ($MRK) Remicade with its biosimilar, Remsima. And now, it's armed with real-world data that could help further that aim.

In 10 real-world studies spanning 600 irritable bowel disease patients in 8 countries, Remsima proved no less safe or effective for patients who switched to the biosim from Remicade, according to the Korean drugmaker. And Celltrion believes that data makes its case for switching more patients to the cheaper therapy.

On top of those results, the company has been "delighted to see a corresponding growth in physician confidence with monoclonal antibody biosimilars, and in willingness to switch to a biosimilar from the originator," CEO Man Hoon Kim said in a statement. "This suggests that more patients will get the chance to benefit from biological therapies, particularly for conditions that require chronic treatment such as IBD."

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Merck may not be so pleased. The company has already taken a hit on Remsima's behalf, with fourth-quarter sales of Remicade dropping 29% to $396 million--an 18% slump at constant exchange rates. For all of 2015, Remicade brought in $1.79 billion, down from $2.37 billion the year prior.

Partner Johnson & Johnson ($JNJ), which sells Remicade in the U.S., is banking on patients staying put even after the Celltrion drug wins FDA approval. As CEO Alex Gorsky outlined earlier this year, J&J believes 70% of its Remicade patients "have a pretty high satisfaction rate"--which would mean the population likely to make a switch is only in the 30% range.

Or so J&J hopes. The company is already taking a beating thanks to hefty competition to former hep C star Olysio, and a strong dollar has been dragging down sales, too.

- read the release

Special Report: The 10 best-selling drugs of 2013 - Remicade

Read more on

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.